{"title":"《柳叶刀肿瘤学杂志》2024年更正；25: 1625 - 34","authors":"","doi":"10.1016/s1470-2045(24)00713-7","DOIUrl":null,"url":null,"abstract":"<em>Vora S, Pafundi D, Voss M, et al. Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.</em> Lancet Oncol <em>2024; <strong>25</strong>: <em>1625–34</em>—In this Article, the spelling of author Bernard R Bendok's name was incorrect. This correction has been made to the online version as of Jan 2, 2025.</em>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2024; 25: 1625–34\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(24)00713-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Vora S, Pafundi D, Voss M, et al. Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.</em> Lancet Oncol <em>2024; <strong>25</strong>: <em>1625–34</em>—In this Article, the spelling of author Bernard R Bendok's name was incorrect. This correction has been made to the online version as of Jan 2, 2025.</em>\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(24)00713-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00713-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vora S, Pafundi D, Voss M, et al. Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial. Lancet Oncol 2024; 25: 1625–34—In this Article, the spelling of author Bernard R Bendok's name was incorrect. This correction has been made to the online version as of Jan 2, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
